New construction of in vivo reprogramming technology by modified microRNA

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K15496
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Digestive surgery
• Research Institution: Osaka University
• Principal Investigator: ISHII Hideshi 大阪大学, 医学系研究科, 特任教授(常勤) (10280736)
• Co-Investigator(Renkei-kenkyūsha): Mori Masaki 大阪大学, 大学院医学系研究科, 教授 (70190999) ; Obika Satoshi 大阪大学, 大学院薬学系研究科, 教授 (80243252) ; Nishiyama Nobuhiro 東京工業大学, 化学生命科学研究所, 教授 (10372385)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: 癌 / 核酸 / ゲノム

Outline of Final Research Achievements

In order to optimize endogenous microRNAs expressed in embryonic phase as pharmaceuticals, crosslinked modification as covalent bonds and others and drug delivery system (DDS) have been constructed (patented). Applicable range embodies direct reprogramming of somatic cells including cancer cell culture in vitro and animal model in vivo. The innovative cell modification based on the epigenetic control by nucleotide medicine will be valuable for the construction of a new therapeutic strategy and innovative disease control, as well as acceleration to drug optimization and corporative relocation, towards the future clinical application.

Free Research Field

外科学